Rx (Prescription Medicine)
USD $ 1,300.00
Hemlibra 150mg Injection 是一种突破性药物，用于治疗血友病 A，这是一种遗传性出血性疾病。其活性成分是异米定（emicizumab），这是一种双特异性单克隆抗体，能够模拟缺失的凝血因子 VIII 的功能。通过连接活化的因子 IX 和因子 X，异米定促进前凝血酶转化为凝血酶，从而促进有效的血栓形成，并降低出血发作的频率。Hemlibra 适用于患有血友病 A（伴或不伴因子 VIII 抑制剂）的患者的常规预防性治疗，以防止或减少出血频率。剂量和给药方式应由医疗专业人员根据患者的体重和临床反应来确定。常见的不良反应可能包括注射部位反应、头痛和关节疼痛。必须按照生产商的说明进行储存，通常需要冷藏并避光保存。在更改治疗方案之前，请务必咨询医生以获得个性化的医疗建议。
| Medicine Form | |
|---|---|
| Rx Status | |
| Medicine Type | |
| Molecule | |
| Brand Name | |
| Pack Quantity | |
| Country Of Origin | |
| Packaging Type | |
| Strength |
未库存此 exact 强度的其他品牌，因此这些是其他强度的 Emicizumab. 未经开方医生建议，请勿更改剂量。
医学审核
Renu Meena, B.Pharm
Medical Content Writer
Renu Meena is an experienced Medical Content Writer with a strong foundation in pharmacy practice. She holds a Bachelor of Pharmacy (B.Pharm) degree from Rajasthan University of Health Sciences (RUHS), Jaipur, and is registered with the Rajasthan State Pharmacy Council (Reg. No. 55661). With 4+ years of experience across clinical pharmacy and medical content development, she creates evidence-based content for medicines, diseases, and patient education. Her work is shaped by a strong understanding of pharmacovigilance and regulatory standards, including ICH guidelines, GVP modules, ICD-10/11, and safety reporting requirements. Renu focuses on making complex medical information simple, accurate, and useful for readers while maintaining high quality and compliance.
